Cargando…

Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5

Alport syndrome-diffuse leiomyomatosis is a rare type of X-linked Alport syndrome resulting from contiguous deletions of 5′ exons of COL4A5 and COL4A6. Studies have suggested that the occurrence of diffuse leiomyomatosis is associated with the characteristic localisation of the COL4A6 gene deletion...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xi, Wang, Jingjing, Mao, Jianhua, Ye, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578185/
https://www.ncbi.nlm.nih.gov/pubmed/34778325
http://dx.doi.org/10.3389/fmed.2021.766224
_version_ 1784596221912940544
author Zhou, Xi
Wang, Jingjing
Mao, Jianhua
Ye, Qing
author_facet Zhou, Xi
Wang, Jingjing
Mao, Jianhua
Ye, Qing
author_sort Zhou, Xi
collection PubMed
description Alport syndrome-diffuse leiomyomatosis is a rare type of X-linked Alport syndrome resulting from contiguous deletions of 5′ exons of COL4A5 and COL4A6. Studies have suggested that the occurrence of diffuse leiomyomatosis is associated with the characteristic localisation of the COL4A6 gene deletion break point. An electronic database was searched for all studies accessing AS-DL to analyze the clinical characteristics, gene deletion break points of patients with AS-DL, and the pathogenesis of AS-DL. It was found that the proportion of de novo mutations of AS-DL was significantly higher in female probands than male probands (78 vs. 44%). Female patients with AS-DL had a mild clinical presentation. The incidence of proteinuria and ocular abnormalities was much lower in female probands than in male probands, and there was generally no sensorineural hearing loss or chronic kidney disease (CKD), which progressed to Stage 3 in female probands. The contiguous deletion of the 5' exons of COL4A5 and COL4A6, with the break point within the intron 3 of COL4A6, was the critical genetic defect causing AS-DL. However, the pathogenesis of characteristic deletion of COL4A6 that contributes to diffuse leiomyomatosis is still unknown. In addition, characteristic contiguous deletion of COL4A5 and COL4A6 genes in AS-DL may be related to transposed elements (TEs).
format Online
Article
Text
id pubmed-8578185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85781852021-11-11 Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5 Zhou, Xi Wang, Jingjing Mao, Jianhua Ye, Qing Front Med (Lausanne) Medicine Alport syndrome-diffuse leiomyomatosis is a rare type of X-linked Alport syndrome resulting from contiguous deletions of 5′ exons of COL4A5 and COL4A6. Studies have suggested that the occurrence of diffuse leiomyomatosis is associated with the characteristic localisation of the COL4A6 gene deletion break point. An electronic database was searched for all studies accessing AS-DL to analyze the clinical characteristics, gene deletion break points of patients with AS-DL, and the pathogenesis of AS-DL. It was found that the proportion of de novo mutations of AS-DL was significantly higher in female probands than male probands (78 vs. 44%). Female patients with AS-DL had a mild clinical presentation. The incidence of proteinuria and ocular abnormalities was much lower in female probands than in male probands, and there was generally no sensorineural hearing loss or chronic kidney disease (CKD), which progressed to Stage 3 in female probands. The contiguous deletion of the 5' exons of COL4A5 and COL4A6, with the break point within the intron 3 of COL4A6, was the critical genetic defect causing AS-DL. However, the pathogenesis of characteristic deletion of COL4A6 that contributes to diffuse leiomyomatosis is still unknown. In addition, characteristic contiguous deletion of COL4A5 and COL4A6 genes in AS-DL may be related to transposed elements (TEs). Frontiers Media S.A. 2021-10-27 /pmc/articles/PMC8578185/ /pubmed/34778325 http://dx.doi.org/10.3389/fmed.2021.766224 Text en Copyright © 2021 Zhou, Wang, Mao and Ye. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Zhou, Xi
Wang, Jingjing
Mao, Jianhua
Ye, Qing
Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5
title Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5
title_full Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5
title_fullStr Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5
title_full_unstemmed Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5
title_short Clinical Manifestations of Alport Syndrome-Diffuse Leiomyomatosis Patients With Contiguous Gene Deletions in COL4A6 and COL4A5
title_sort clinical manifestations of alport syndrome-diffuse leiomyomatosis patients with contiguous gene deletions in col4a6 and col4a5
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578185/
https://www.ncbi.nlm.nih.gov/pubmed/34778325
http://dx.doi.org/10.3389/fmed.2021.766224
work_keys_str_mv AT zhouxi clinicalmanifestationsofalportsyndromediffuseleiomyomatosispatientswithcontiguousgenedeletionsincol4a6andcol4a5
AT wangjingjing clinicalmanifestationsofalportsyndromediffuseleiomyomatosispatientswithcontiguousgenedeletionsincol4a6andcol4a5
AT maojianhua clinicalmanifestationsofalportsyndromediffuseleiomyomatosispatientswithcontiguousgenedeletionsincol4a6andcol4a5
AT yeqing clinicalmanifestationsofalportsyndromediffuseleiomyomatosispatientswithcontiguousgenedeletionsincol4a6andcol4a5